Humasis Co (205470) Fair Value & Analysis
Healthcare · KR · Market cap 61.9B KRW
Fair value as of: Jul 7, 2026
From 7 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 42,764 KRW to 3,832 KRW (−91.0%) since Jun 24, 2026. Share price −28.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 2,100 KRW – 9,495 KRW · fair‑value band 2,635 KRW – 5,030 KRW · the 2,305 KRW price screens below the 3,832 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Humasis Co (205470) currently trades at 2,305 KRW, while our model-based Fair Value estimate is 3,832 KRW — implying the stock looks roughly 66.3% undervalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Humasis Co generated revenue of 32.9B KRW at a net margin of -31.7%. Revenue grew 44.8% year over year. It earns a return on equity of -6.5%. Net debt stands at 3.6B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 2,635 KRW (bear case) to 5,030 KRW (bull case); at 2,305 KRW, the current price sits below that range. The share trades about 71% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside — at 66%, 205470 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Humasis Co reported revenue of 30.1B KRW in FY2025 versus 322B KRW in FY2021, a compound −44.7%/yr. Reported net income was −15.6B KRW in FY2025.
Is 205470 fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$37.76 | R$6.34 | -83% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| DexCom, Inc DXCM | $72.59 | $39.33 | -46% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Humasis Co (205470) undervalued?
What is the fair value of 205470?
What is the quality score of 205470?
What is the revenue of Humasis Co (205470)?
What is the net profit margin of 205470?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.